MICA and ovarian carcinoma: Similarly, PARP1 inhibitors have shown significant antitumor activity in various cancers, including breast and ovarian cancers, primarily by disrupting DNA repair mechanisms.[21] However, there is a noticeable gap in the literature regarding whether the combination of PIM‐2 inhibitors and PARP1 inhibitors could intensify DNA damage, enhance MICA expression on tumor cells, and subsequently activate NK cell‐mediated cytotoxicity.